Alcoholism
Conditions
Keywords
alcoholism, lung health, pulmonary, macrophage, zinc, SAMe, S-adenosylmethionine, alveolar
Brief summary
This is a randomized, placebo controlled trial of dietary zinc and S-adenosylmethionine (SAMe) in otherwise healthy alcoholic US Veterans. The primary goal is to determine if either dietary zinc or S-adenosylmethionine (SAMe) can augment lung immune defenses in alcoholics and thereby decrease the risk of lung injury and infection.
Detailed description
Alcohol abuse is a major burden on society and even more of a problem in the Veteran population. Chronic alcohol ingestion can have serious health consequences including pneumonia and acute lung injury, which can occur suddenly and without warning even in physically fit individuals without apparent signs of alcohol dependence. Therefore, it is vital for the health of our Veterans and indeed the entire population to identify effective treatments that can limit or even prevent these devastating consequences. The primary goal of this clinical research project is to determine if dietary zinc or supplements of the antioxidant S-adenosylmethionine (SAMe) can augment lung immune defenses in otherwise healthy alcoholics and thereby decrease the risk of lung injury and infection. There is already strong evidence from the investigators' experimental animal model that moderate daily alcohol ingestion for as little as six weeks causes oxidative stress and zinc deficiency in the lung. These derangements result insult in dysfunction of the alveolar macrophage, which is the resident immune cell, and predisposes animals to the development of pneumonia. Importantly, in this same animal model, the investigators found that adding either zinc or antioxidants to the diet prevents these problems and preserves lung health even during daily alcohol ingestion. This project will translate basic findings in the animal model to the clinical setting and determine whether or not zinc or SAMe supplements are effective in humans who pathologically consume alcohol. This project will enroll Veterans seen at the Atlanta Veterans Hospital in the Substance Abuse Treatment Program (SATP). Participants will be evaluated by undergoing a procedure to obtain samples of fluid from their lungs, measure zinc levels, redox potential, and assess how well their alveolar macrophages respond to bacteria (by determining phagocytic capacity). After completion of the initial evaluation, the participants will be randomized to receive standard treatment (placebo), zinc supplements, dietary SAMe, or the combination of zinc and SAMe for 14 days. All subjects will be evaluated for two weeks as they undergo treatment. At the end of this two week period, measurements of lung zinc, redox potential and macrophage function will be repeated and compared between the two groups. The hypothesis is that both dietary zinc and SAM supplements will improve the immune function of the alveolar macrophage. If this project is successful, it will lead to larger clinical trials to determine if either dietary zinc and/or SAMe supplements can be effective even in the acute clinical setting and improve outcomes in alcoholics who develop pneumonia or acute lung injury. Overall, both zinc and SAMe supplements are safe and inexpensive to provide, allowing these potential treatments to be easily implemented in the Veteran population as well as society in general. Given the significant burden of unhealthy alcohol use, the investigators need ways to limit the physical consequences of alcohol abuse while the investigators continue the efforts at public education and addiction treatment.
Interventions
Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age 18-60 years * Active alcohol use disorder
Exclusion criteria
* Any active and uncontrolled medical problem(s) * Known zinc deficiency * Primary substance of abuse something other than alcohol * Current abnormal chest x-ray * HIV-positive * Any disorder of blood coagulation * Currently on medical treatment with anti-coagulants, including: * warfarin * heparin * direct thrombin inhibitors * anti-platelet agents (other than Aspirin) * Daily use of vitamins or other nutritional supplements (unless taking as treatment for alcohol use disorder) * Renal impairment (GFR \< 60) * Active bipolar disorder * Active Parkinson's disease * Current pregnancy * Contraindication to treatment with zinc or S-adenosylmethionine * Inability to give informed consent (i.e., limited cognitive capacity) * Non-English speaking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Endpoint | Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment) | Improvement in alveolar macrophage phagocytic index. Phagocytic index will be measured before and after treatment phase. Phagocytic index is calculated using isolated alveolar macrophages from the bronchoscopy procedure such that phagocytic index = (total number of engulfed cells/total number of counted macrophages) x (number of macrophages containing engulfed cells/total number of counted macrophages) x 100. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Endpoint | Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment) | Improvement in alveolar macrophage intracellular zinc. Intracellular zinc will be measured before and after treatment phase using isolated alveolar macrophages. The units of measure are relative fluorescence units/cell (RFU/cell) and measured using confocal microscopy techniques. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Secondary Endpoint | Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment) | Improvement in redox potential in the alveolar space. Redox potential will be measured before and after treatment phase using lavage fluid and blood plasma. |
Countries
United States
Participant flow
Pre-assignment details
Participants are enrolled when they sign consent, however, only get randomized after completing first bronchoscopy procedure. Therefore, there were some participants who enrolled but never completed the procedure in order to be randomized into a group. This is the reason for the discrepancy in numbers.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Zinc and Placebo SAMe Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques. | 23 |
| Active Zinc and Placebo SAMe Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
Zinc sulfate 220 mg once daily | 25 |
| Placebo Zinc and Active SAMe Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
S-adenosylmethionine 400 mg twice daily | 25 |
| Active Zinc and Active SAMe Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
Zinc sulfate 220 mg once daily
S-adenosylmethionine 400 mg twice daily | 22 |
| Total | 95 |
Baseline characteristics
| Characteristic | Total | Placebo Zinc and Placebo SAMe | Active Zinc and Placebo SAMe | Placebo Zinc and Active SAMe | Active Zinc and Active SAMe |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 95 Participants | 23 Participants | 25 Participants | 25 Participants | 22 Participants |
| Age, Continuous | 48 years | 46 years | 47 years | 47 years | 51 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 92 Participants | 22 Participants | 25 Participants | 24 Participants | 21 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 77 Participants | 17 Participants | 20 Participants | 21 Participants | 19 Participants |
| Race (NIH/OMB) More than one race | 7 Participants | 2 Participants | 3 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 10 Participants | 4 Participants | 2 Participants | 2 Participants | 2 Participants |
| Region of Enrollment United States | 95 participants | 23 participants | 25 participants | 25 participants | 22 participants |
| Sex: Female, Male Female | 15 Participants | 2 Participants | 4 Participants | 5 Participants | 4 Participants |
| Sex: Female, Male Male | 80 Participants | 21 Participants | 21 Participants | 20 Participants | 18 Participants |
| Smoking Status Non-smoker | 37 Participants | 9 Participants | 10 Participants | 10 Participants | 8 Participants |
| Smoking Status Smoker | 58 Participants | 14 Participants | 15 Participants | 15 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 23 | 0 / 25 | 0 / 25 | 0 / 22 |
| other Total, other adverse events | 17 / 23 | 21 / 25 | 16 / 25 | 16 / 22 |
| serious Total, serious adverse events | 1 / 23 | 0 / 25 | 1 / 25 | 0 / 22 |
Outcome results
Primary Endpoint
Improvement in alveolar macrophage phagocytic index. Phagocytic index will be measured before and after treatment phase. Phagocytic index is calculated using isolated alveolar macrophages from the bronchoscopy procedure such that phagocytic index = (total number of engulfed cells/total number of counted macrophages) x (number of macrophages containing engulfed cells/total number of counted macrophages) x 100.
Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Zinc and Placebo SAMe | Primary Endpoint | Pre-treatment PI | 13518 Phagocytic Index (PI) | Standard Deviation 11677 |
| Placebo Zinc and Placebo SAMe | Primary Endpoint | Post-treatment PI | 16704 Phagocytic Index (PI) | Standard Deviation 15412 |
| Active Zinc and Placebo SAMe | Primary Endpoint | Post-treatment PI | 23850 Phagocytic Index (PI) | Standard Deviation 47703 |
| Active Zinc and Placebo SAMe | Primary Endpoint | Pre-treatment PI | 15892 Phagocytic Index (PI) | Standard Deviation 18961 |
| Placebo Zinc and Active SAMe | Primary Endpoint | Post-treatment PI | 10734 Phagocytic Index (PI) | Standard Deviation 9709 |
| Placebo Zinc and Active SAMe | Primary Endpoint | Pre-treatment PI | 10849 Phagocytic Index (PI) | Standard Deviation 11087 |
| Active Zinc and Active SAMe | Primary Endpoint | Pre-treatment PI | 15530 Phagocytic Index (PI) | Standard Deviation 17627 |
| Active Zinc and Active SAMe | Primary Endpoint | Post-treatment PI | 13955 Phagocytic Index (PI) | Standard Deviation 14511 |
Secondary Endpoint
Improvement in alveolar macrophage intracellular zinc. Intracellular zinc will be measured before and after treatment phase using isolated alveolar macrophages. The units of measure are relative fluorescence units/cell (RFU/cell) and measured using confocal microscopy techniques.
Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Zinc and Placebo SAMe | Secondary Endpoint | Pre-treatment Intracellular Zinc | 2816 RFU/cell | Standard Deviation 2149 |
| Placebo Zinc and Placebo SAMe | Secondary Endpoint | Post-treatment Intracellular Zinc | 2710 RFU/cell | Standard Deviation 1980 |
| Active Zinc and Placebo SAMe | Secondary Endpoint | Post-treatment Intracellular Zinc | 3510 RFU/cell | Standard Deviation 2590 |
| Active Zinc and Placebo SAMe | Secondary Endpoint | Pre-treatment Intracellular Zinc | 3410 RFU/cell | Standard Deviation 2655 |
| Placebo Zinc and Active SAMe | Secondary Endpoint | Pre-treatment Intracellular Zinc | 3883 RFU/cell | Standard Deviation 2723 |
| Placebo Zinc and Active SAMe | Secondary Endpoint | Post-treatment Intracellular Zinc | 4327 RFU/cell | Standard Deviation 3092 |
| Active Zinc and Active SAMe | Secondary Endpoint | Pre-treatment Intracellular Zinc | 4174 RFU/cell | Standard Deviation 3386 |
| Active Zinc and Active SAMe | Secondary Endpoint | Post-treatment Intracellular Zinc | 3103 RFU/cell | Standard Deviation 2823 |
Secondary Endpoint
Improvement in redox potential in the alveolar space. Redox potential will be measured before and after treatment phase using lavage fluid and blood plasma.
Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Zinc and Placebo SAMe | Secondary Endpoint | Pre-treatment GSSG | 33.0 GSSG percentage (measure of oxidation) | Standard Deviation 30.5 |
| Placebo Zinc and Placebo SAMe | Secondary Endpoint | Post-treatment GSSG | 28.9 GSSG percentage (measure of oxidation) | Standard Deviation 29.2 |
| Active Zinc and Placebo SAMe | Secondary Endpoint | Post-treatment GSSG | 19.7 GSSG percentage (measure of oxidation) | Standard Deviation 23.8 |
| Active Zinc and Placebo SAMe | Secondary Endpoint | Pre-treatment GSSG | 28.0 GSSG percentage (measure of oxidation) | Standard Deviation 29.2 |
| Placebo Zinc and Active SAMe | Secondary Endpoint | Pre-treatment GSSG | 21.6 GSSG percentage (measure of oxidation) | Standard Deviation 25.3 |
| Placebo Zinc and Active SAMe | Secondary Endpoint | Post-treatment GSSG | 20.5 GSSG percentage (measure of oxidation) | Standard Deviation 26.8 |
| Active Zinc and Active SAMe | Secondary Endpoint | Pre-treatment GSSG | 28.5 GSSG percentage (measure of oxidation) | Standard Deviation 30.6 |
| Active Zinc and Active SAMe | Secondary Endpoint | Post-treatment GSSG | 33.5 GSSG percentage (measure of oxidation) | Standard Deviation 35.2 |
Secondary Endpoint
Improvement in alveolar macrophage granulocyte macrophage - colony stimulating factor (GM-CSF) receptor expression. GM-CSF receptor expression will be measured before and after treatment phase using isolated alveolar macrophages. The units of measure are relative fluorescence units/cell (RFU/cell) and measured using confocal microscopy techniques. Both alpha- and beta-subunits of the receptor will be measured.
Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)
Population: The cells were not stained appropriately, so this secondary measure could not be completed because the results were not analyzable.
Secondary Endpoint
Improvement in serum zinc level. Serum zinc will be measured before and after treatment phase by collecting blood plasma. The units of measure are mcg/dl.
Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Zinc and Placebo SAMe | Secondary Endpoint | Pre-treatment Serum Zinc | 79.5 mcg/dl | Standard Deviation 18.5 |
| Placebo Zinc and Placebo SAMe | Secondary Endpoint | Post-treatment Serum Zinc | 71.2 mcg/dl | Standard Deviation 9.7 |
| Active Zinc and Placebo SAMe | Secondary Endpoint | Post-treatment Serum Zinc | 95.6 mcg/dl | Standard Deviation 36.3 |
| Active Zinc and Placebo SAMe | Secondary Endpoint | Pre-treatment Serum Zinc | 76.9 mcg/dl | Standard Deviation 12 |
| Placebo Zinc and Active SAMe | Secondary Endpoint | Pre-treatment Serum Zinc | 78.5 mcg/dl | Standard Deviation 12.1 |
| Placebo Zinc and Active SAMe | Secondary Endpoint | Post-treatment Serum Zinc | 80.1 mcg/dl | Standard Deviation 14.9 |
| Active Zinc and Active SAMe | Secondary Endpoint | Pre-treatment Serum Zinc | 75.0 mcg/dl | Standard Deviation 11 |
| Active Zinc and Active SAMe | Secondary Endpoint | Post-treatment Serum Zinc | 92.0 mcg/dl | Standard Deviation 34.8 |